13th Aug 2013 07:00
13 August 2013 | AIM: RENE |
ReNeuron Group plc
(the "Company")
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | ReNeuron Group plc | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | X | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | ||||
3. Full name of person(s) subject to thenotification obligation: | Abingworth LLP Abingworth Bioventures VI LP Abingworth Bioequities Master Fund Limited | |||
4. Full name of shareholder(s) (if different from 3.): | Bank of New York (Nominees) Limited (as nominee for Abingworth Bioventures VI LP)
Jefferies & Co Inc. (as nominee for Abingworth Bioequities Master Fund Limited)
| |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 9 August 2013 | |||
6. Date on which issuer notified: | 12 August 2013 | |||
7. Threshold(s) that is/are crossed orreached: | Above 5% threshold - Abingworth LLP Above 4% threshold - Abingworth Bioequities Master Fund Limited | |||
8. Notified details: Abingworth LLP | ||||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||||
ReNeuron Group plc
| 0 | 0 | 90,000,000 | 5.03% | ||||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||||
| Nominal | Delta | ||||||||||||||||
Total (A+B+C) | ||||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||||
90,000,000 | 5.03% | |||||||||||||||||
8. Notified details: Abingworth Bioequities Master Fund Limited | ||||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||||
ReNeuron Group plc
| 0 | 0 | 80,000,000 | 80,000,000 | 4.47% | |||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights | |||||||||||||
| Nominal | Delta | ||||||||||||||||
Total (A+B+C) | ||||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||||
80,000,000 | 4.47% | |||||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
Abingworth Bioventures VI LP (which holds 10,000,000 shares in the company (0.56%)) and Abingworth Bioequities Master Fund Limited (which holds 80,000,000 shares in the company (4.47%)) are both managed by Abingworth LLP.
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | ||
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | ||
14. Contact name: | John Heard | |
15. Contact telephone number: | 0207 534 1508 | |
Related Shares:
RENE.L